HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- hydroxy- N- (2,3- dihydro- 6- phenylmethoxy- 3- benzofuranyl)urea

a selective 5-lipoxygenase inhibitor; structure given in first source

Also Known As:

SB 202235; SB-202235

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzofurans: 26
      - N-hydroxy-N-(2,3-dihydro-6-phenylmethoxy-3-benzofuranyl)urea: 2
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - N-hydroxy-N-(2,3-dihydro-6-phenylmethoxy-3-benzofuranyl)urea: 2

Experts

1.	Johnson, C M: 1 article (03/2000)
2.	Posobiec, L M: 1 article (03/2000)
3.	Rendemonti, J E: 1 article (03/2000)
4.	Rumberger, D F: 1 article (03/2000)
5.	Solomon, H M: 1 article (03/2000)
6.	Wier, P J: 1 article (03/2000)

Related Diseases

1.	Fetal Weight 03/01/2000 - "SB-202235 (1,000 mg/kg/day) and SB-210661 (50 and 100 mg/kg/day) reduced fetal body weight by 15-30% and produced extensive cardiovascular malformations, as well as diaphragmatic hernias. "
2.	Diaphragmatic Hernia 03/01/2000 - "SB-202235 (1,000 mg/kg/day) and SB-210661 (50 and 100 mg/kg/day) reduced fetal body weight by 15-30% and produced extensive cardiovascular malformations, as well as diaphragmatic hernias. "
3.	Body Weight (Weight, Body) 03/01/2000 - "SB-202235 (1,000 mg/kg/day) and SB-210661 (100 mg/kg/day) reduced maternal body weight gain for the treatment period by 16% and 21%, respectively, relative to controls. "
4.	Asthma (Bronchial Asthma) 06/01/1995 - "In addition, the potential therapeutic value of SB 202235 was assessed in preclinical models of allergic asthma. " 06/01/1995 - "Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma."

Related Drugs and Biologics

1.	Lipoxygenase Inhibitors
2.	SB 210661